Evidence map›Paper›PMID 41028930›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

A Multicenter Validation of a Fully Automated Chemiluminescence Immunoassay for Plasma Elafin in Psoriasis Diagnosis and Severity Assessment.

Jingkun Yi, Meng Xu, Ling Han, Zhining Dong, Ruimin Liu, Xiaomei Zhang, Di Hu, Chuanjian Lu, Xiaobo Yu

Abstract readMulticenter StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jingkun YiState Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.ORCID https://orcid.org/0000-0003-0675-8456
Meng XuState Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.
Ling HanThe Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510000, China.
Zhining DongGuangzhou DARUl Biotechnology Co., Ltd, Guangzhou, Guangdong, 510000, China.
Ruimin LiuHebei University, Baoding, Hebei, 071002, China.
Xiaomei ZhangState Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.
Di HuProteomicsEra Medical Co., Ltd, Beijing, 102206, China.
Chuanjian LuState Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510120, China.
Xiaobo YuState Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.ORCID https://orcid.org/0000-0003-2352-9866

Funding

Beijing Municipal International Cooperation and Exchange Project Z231100002723004Beijing Municipal Natural Science Foundation L234034Beijing Municipal Natural Science Foundation M23010Guangdong-PHOENIX Center Joint Lab on Chinese Medicine YN2021DB06Guangdong Province Science and Technology Planning Project 2020B1111100006National Key R&D Program of China 2021YFA1301604National Key R&D Program of China 2022YFE0210400National Key R&D Program of China 2024YFA1307600National Key R&D Program of China 2024YFA1307601National Natural Science Foundation of China 82572077PHOENIX Center and Guangdong Provincial Hospital of Chinese Medicine YN2018DB01PHOENIX Center and Guangdong Provincial Hospital of Chinese Medicine YN2021DB03
6 · The paper itself

Abstract

Psoriasis diagnosis and severity assessment rely on subjective skin evaluations. Elafin is a promising biomarker, yet no high-throughput clinical assay exists. A chemiluminescence immunoassay (CLIA) reagent kit for plasma Elafin has been developed and validated using automated analyzers to enable rapid diagnosis, objective severity stratification, and longitudinal monitoring. Analytical performance is rigorously assessed, including the limit of blank (LoB) (0.069 ng mL

Indexed as

ElafinLuminescent MeasurementsPsoriasisAdolescentAdultAgedBiomarkersFemaleHumansImmunoassayMaleMiddle AgedReproducibility of ResultsSeverity of Illness IndexBiomarkersElafinfull‑course managementfully automated chemiluminescence immunoassayspsoriasis

Identifiers

PMID41028930
PMCPMC12713042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.